600 patients67,035 observations120 daysLIVE

Patient P-01308

Synthetic patientNBL-101 · Day 111 · 75+ · M · baseline S16Steering view · 3DOpen companion preview
Is the drug working?

Therapy response 78 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 77%, therapy response 77 today; biology is not blocking the drug.

Is a side effect starting?

Drift detected on day 13 (HRV −10 ms, resting HR +4 bpm, sleep −1.1 h, gi toxicity +24, inflammatory load +24); the side effect would have been reported on day 17 — 4 days of warning.

Still taking it?

8 of 8 scheduled doses in the last 60 days are biologically confirmed (100%). Dose signature: resting HR +3 bpm, HRV −11 ms.

last 8 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 118Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
98% improving

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-01308 is on day 111 of NBL-101 (EC-02, baseline S16): response favorable, tolerance favorable, GI improving. Over 14 days response moved 0 and GI -14; discontinuation risk is 2%. The state is in the restoration basin, heading towards restoration, after diverging from the model on day 13.

Biology sets the gain: IL6 high-expression variant; butyrate capacity 79/100, diversity 3.0. Pushing it down: Bacteroides fragilis elevated (-11.5), IL6 high-expression variant (-11.4), Simple carbohydrates (-7.8). Pulling it up: Butyrate producers intact (+11.6). From the daily log: simple carbs +2.8 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Favorable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
2%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (weekly infusion, day 1 of each 7-day cycle)
  1. Day 0 NBL-101 startedBaseline state S16
  2. Day 13 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 13.

Primary contributors, last 14 days
  • GI instability-14
  • Inflammatory activity-10
  • Nutritional resilience+9
  • Treatment adherence+2

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    5.1/100
    improving · -3.4 vs previous 14 d
    Toxicity
    Blood
    11.6/100
    improving · -16.3 vs previous 14 d
    Sleep quality
    Wearable
    68.3/100
    improving · +7.0 vs previous 14 d
    Energy level
    Daily log
    6.8/10
    improving · +0.7 vs previous 14 d
    Stress level
    Daily log
    1.9/10
    improving · -0.6 vs previous 14 d
    Steps
    Wearable
    4,594
    improving · +467 vs previous 14 d
    Adherence
    Companion
    97.5 %
    improving · +7.2 vs previous 14 d
    This trajectory is doing well — what to keep, what to watch
    Steering view →

    Heading towards restoration · 97 from the failing basin, 15 from restoration.

    Good elements to keep
    • Butyrate producers intact
      hidden · steering +11.6
    Main detractors to watch
    • Bacteroides fragilis elevated
      hidden · steering -11.5
    • IL6 high-expression variant
      hidden · steering -11.4
    • Simple carbohydrates
      perturbation · steering -7.8
    • Dietary drift
      perturbation · steering -2.6
    • Simple carbohydrates
      detractor · GI +2.8 next day
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Simple carbohydrates
      +2.8detractor · 59%
    • Alcohol
      +1.8no signal · 34%
    • Spicy / capsaicin
      +1.7no signal · 34%
    • Histamine load
      +1no signal · 16%
    • Dietary fat load
      +0.7no signal · 15%
    • Insoluble fibre
      +0.4no signal · 15%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    9/100
    vs baseline (day 0)
    -30
    8 improved · 0 worsened
    synthetic signature · consistent with this patient's biology
    • 1 keystone species absent
    • 3 resistance genes
    Pathogens / opportunists0/5
    from 3
    Keystone species1/8
    from 2
    Diversity0/2
    from 1
    Metabolic modules0/4
    Vitamin synthesis1/7
    Oral translocation0/1
    from 1
    Host DNA0/1
    Tissue recycling0/1
    Central mechanisms0/2
    Virulence factors1/1
    from 2
    Antibiotic resistance genes3/3
    from 4
    Genetic predisposition2/2
    Opportunists above range
    none
    Keystone species absent
    Akkermansia muciniphila
    Capacity
    Shannon 3.32 · butyrate 847 CPM · SCFA 1356
    1 vitamins below
    Host & mechanisms
    tissue recycling 29/100
    oral translocation 1.5% AR
    3 resistance genes · 1 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Inflammatory signalling 45
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • MicrobiomeBacteroides fragilis expansion
    • Mucosal barrier integrity 30
      • MicrobiomeAkkermansia low → thinner mucus layer
    • Butyrate / short-chain fatty acid production 25
      • MicrobiomeF. prausnitzii depleted
    DNA
    Fictional pharmacogenomic panel
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Normal metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 3 · butyrate capacity 79/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisHigh
    • Bifidobacterium longumLow
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    71 ms
    Sleep
    6.8 h
    Steps
    5,305
    Resting HR
    60 bpm
    Daily log: GI score 5, nutritional resilience 73, adherence 98.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Log the daily check-in; one line is enough
    • A 15-minute walk after lunch
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0148140%S15AD-05no change67
    P-0146827%S03AD-05no change50
    P-0145026%S18AD-05no change45
    P-0141146%S13BR-03no change76
    P-0148940%S05BR-03improved83
    P-0176439%S15BR-03no change85
    P-0176635%S01BR-03improved83
    P-0166443%S07CR-01improved85
    P-0189641%S06CR-01improved73
    P-0147244%S20DT-01no change82
    P-0142839%S18DT-01improved82
    P-0152833%S20DT-01improved89